Medical/Pharmaceuticals
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...
2021-11-12 07:55
4489
Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics
SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry andin-vitro ADME Service offerings. Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small mo...
2021-11-11 21:33
3578
Dr. Ivan Puah developed MDC-Sculpt(R) Lipo technique to achieve optimal liposuction results in patients
SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- Dr Ivan Puah, Medical Director at Amaris B. Clinic, who has been performing liposuction, correction surgery and gynecomastia surgery for more than 15 years, has developed a liposuction technique called MDC-Sculpt®️ Lipo technique. This proprietary appro...
2021-11-11 16:52
2807
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
SHANGHAI, Nov. 11, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD) jointly announces today that Everest Medicines sponsored (HKEX 1952.HK) Phase2b EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy® in the United States) met its primary endpoint o...
2021-11-11 08:05
4548
Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland
BASEL, Switzerland, Nov. 10, 2021 /PRNewswire/ -- Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Zambon Switzerland (Zambon), under which the company grants Zambon exclusive rights to commercialize Rivastigmine Mul...
2021-11-10 23:38
5074
Care Group Acquires Pukekohe Family Health Care to Become Largest Provider of Primary Care in East Auckland
AUCKLAND, New Zealand, Nov. 10, 2021 /PRNewswire/ -- Care Group, a renowned provider and integrator of health services, has acquired Pukekohe Family Health Care (PFHC), a large general practice based in Central Pukekohe. The latest acquisition is in sync with the group's vision to build community...
2021-11-10 21:13
3147
David C. Dvorak is THINK Surgical's New Executive Chairman of the Board of Directors
FREMONT, Calif., Nov. 10, 2021 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the appointment ofDavid C. Dvorak as the Executive Chairman of its Board of Directors. Mr. Dvorak's decades of experience in the medical device industry, ...
2021-11-10 21:00
2001
Lianhua Qingwen Sent to People for Covid-19 Containment by Cambodian Government
PHNOM PENH, Cambodia, Nov. 10, 2021 /PRNewswire/ -- On Sunday, 600 local families in Veal Veaeng District, Pursat Province,Cambodia, got Lianhua Qingwen Capsules, produced by Yiling Pharmaceutical, from Suy Sem, the Cambodian Minister of Mines and Energy, also president of the Cambodian central ...
2021-11-10 20:07
3202
LifeWave Held Amplify Summer Summit 2021
TOKYO, Nov. 10, 2021 /PRNewswire/ -- LifeWave, a U.S.-based global health technology company, hosted a summer conference onAugust 21 and 22, 2021. The conference, dubbedAmplify, focused on LifeWave's products and the company's business opportunities. It was held virtually because of recommendatio...
2021-11-10 11:18
3406
Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients
HANGZHOU, China and SHAOXING, China, Nov. 10, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the approval of the Phase II clinical trial of ASC22 (Envafolimab) by China National Medical Products Administration (NMPA) for the proposed new indication of immune restoration/fu...
2021-11-10 08:30
4039
Smith+Nephew establishes its first Medical Education Centre for the Asia Pacific region in Singapore
LONDON, Nov. 10, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the
global medical technology business, today announces its first dedicated Medical
Education Centre to support customers across theAsia Pacific region.
2021-11-10 08:04
5969
Prenetics Announces Strong First Half 2021 Financial Results as Company Progresses Towards a U.S. Nasdaq Listing in Partnership with Artisan Acquisition Corp.
* Revenue reached US$136.5 million, up 1,039% year-over-year * Adjusted EBITDA was US$31.5 million, increased by US$34.6 million year-over-year * Prenetics has publicly filed a registration statement on Form F-4 with the SEC in connection with its proposed business combination with Artisan ...
2021-11-10 07:34
3147
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-a...
2021-11-09 21:00
4040
Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative
MANASSAS, Va., Nov. 9, 2021 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of theApril...
2021-11-09 20:55
3586
Regrowing Damaged Body Parts: How Osteopore, an Australian-listed Company, is Making it Accessible
SINGAPORE, Nov. 9, 2021 /PRNewswire/ -- Osteopore, an Australian and Singapore based leader in regenerative implants on a commercial scale, is developing technology that enables widespread adoption of tissue engineering. Despite the global average life expectancy rising by more than 6 years betwe...
2021-11-09 18:05
2425
Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting
SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-11-09 16:30
5304
Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern
TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burden, today announced preclinical data...
2021-11-09 10:00
4305
Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study
HANGZHOU, China and SHAOXING, China, Nov. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the interim results of 44 chronic hepatitis B (CHB) patients from a Phase IIb trial of ASC22 (Envafolimab), a subcutaneously administered PD-L1 antibody (ClinicalTrials.gov Ide...
2021-11-09 08:33
4440
CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics
* The two sides will jointly develop up to three preclinical first-in-class or best-in-class next-generation antibody therapies, for which CStone would lead the design of the target combination based on the intended mechanism of action and DotBio will lead the design and engineering of the mole...
2021-11-09 08:05
6118
BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical Countermeasures to Chemical Exposure
LONDON, Nov. 8, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), which provides an integra...
2021-11-08 21:00
3841
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
41927
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
33400
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
17085
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
16389
